OpenAI, the company Sam Altman runs, wrote the biggest check into Merge Labs, the company Sam Altman also co-founded, and nobody at either shop seems bothered by how that looks.

Circular!!!

Cosy in a way that should make a person uncomfortable. But here we are.

A recent industry rundown on where brain implants actually stand this year lays it out plain, no commercial brain-computer interface exists yet, everything running today is research or expanded access, and the realistic timeline for anything you could buy stretches to 2028 or beyond, which is a long way off for a technology that already has hundreds of millions of dollars sloshing around it and a valuation north of eight hundred million resting on a company that hasnt shipped a single device.

Merge came out of stealth back in January with a quarter billion dollars and a mission statement about bridging biology and artificial intelligence, bold words, big words, words that mean nothing until a chip actually reads a thought correctly, and the company said in its own launch announcement that it wants to interface with more neurons at higher bandwidth without cutting anyone open, using ultrasound and molecular tricks instead of electrodes, which sounds elegant until you remember Neuralink already has people playing chess with their minds and Merge has, as far as anyone outside the building knows, a research plan and a founding team.

What Altman is selling isnt a product, its a feeling, the feeling that the next input device wont be a keyboard or a mouse but you, your skull, your blood flow lighting up under a strip of plastic.

BRAIN. COMPUTER. INTERFACE.

Say it slow and it still sounds like a lie someone tells at a dinner party to seem interesting, say it fast and it starts sounding like Tuesday, like just another line item, and thats the part that actually rattles me, how quick the culture absorbed a sentence like "OpenAI invested in the CEO's own brain company" without anybody outside finance twitter blinking twice, WHERE IS THE OUTRAGE, wheres the Senate hearing, wheres anyone asking who owns the data coming off your own neurons once a company youve never heard of is holding it, and then I remember, this is 2026, we stopped asking those questions somewhere around the fourth AI bubble headline and just started buying the dip.

Rich men building toys and calling them destiny.

Neuralink has implants in a dozen or so patients. Synchron has ten. Merge has zero, a lab coat, and Sam Altman's name, which apparently these days functions as its own form of collateral, the kind of asset class you cant find on a balance sheet but every venture fund in the Bay somehow prices in anyway.

Capital has stopped waiting for proof of concept and started paying for proof of narrative instead, which, if you think about it long enough, and I have been thinking about it long enough that it's started to feel less like an investment thesis and more like a fever, means the actual brain-computer interface being built right now isnt made of ultrasound or gene therapy at all, its made of belief, stacked in rounds, priced in valuations, and none of it needs to work yet for the money to already have moved.

That's where it sits. A quarter billion in, zero devices out, and a whole field betting the gap closes before anyone notices it hasnt.